We are keen to progress research that has the potential to change mental health outcomes and help those who have not been helped by other treatments.
To support this, we work in collaboration with select academic institutions and researchers around the world. We provide our cGMP (clinical Good Manufacturing Practice – the highest manufacturing grade) COMP360 psilocybin to researchers free of charge, in exchange for the right to use safety data. Researchers are expected to cover packaging and shipping costs with our logistics provider. For these investigator-initiated studies (IISs), we also provide support with regulatory submissions.
These IISs are signal-generating, exploratory studies looking at indications in areas of unmet need, including anorexia, bipolar disorder II, body dysmorphic disorder, chronic cluster headache, major depressive disorder, and severe treatment-resistant depression.
Our IIS programme is currently full and we will update this page when we are open for new applications. If you have any questions in the meantime, please contact us at email@example.com.
Collaboration is key to developing a new approach to mental health, and this is why we are bringing together health innovators for the benefit of patients.